PRN1371: FGFR1-4 Inhibitor
Solid Tumors

Phase 1

Fibroblast Growth Factor Receptor (FGFR) has been implicated in a number of solid tumors as an area of intense interest including research and development efforts. An increasing body of evidence exists on the role of FGFR in driving tumors in a subset of patients across a wide range of tumor types. Principia has developed an oral, highly potent, selective inhibitor of all four isoforms of FGFR.

  • Ongoing Phase 1 clinical trial in patients with metastatic solid tumors to determine therapeutic dose and safety

  • FGFR, fibroblast growth factor receptors, has an essential role in regulating cell survival, proliferation, migration and differentiation. Aberrant activations of FGFR1-4 pathways have been associated with many types of cancers

  • PRN1371 inhibits all four FGFR isoforms and blocks aberrant FGFR kinase signaling. This broad profile is suitable to treat many tumor types, including but not limited to urothelial, squamous lung, gastric and hepatocellular carcinoma

  • High selectivity to minimize off-target toxicities, ideal for safer combinations with other therapies, including to prevent resistance mechanisms